MARKET

NKTX

NKTX

Nkarta, Inc.
NASDAQ
1.865
+0.025
+1.36%
Opening 14:04 04/01 EDT
OPEN
1.810
PREV CLOSE
1.840
HIGH
1.915
LOW
1.780
VOLUME
881.16K
TURNOVER
--
52 WEEK HIGH
11.84
52 WEEK LOW
1.310
MARKET CAP
132.34M
P/E (TTM)
-1.1634
1D
5D
1M
3M
1Y
5Y
1D
Nkarta to Participate in an April Investor Conference
Barchart · 11h ago
Nkarta: Grinding Lower, Trying To Find Support
Seeking Alpha · 1d ago
Nkarta: Betting On The Turnaround
Seeking Alpha · 1d ago
Weekly Report: what happened at NKTX last week (0324-0328)?
Weekly Report · 1d ago
Analysts Offer Insights on Healthcare Companies: Mereo Biopharma Group Plc (MREO), Tenax Therapeutics (TENX) and Nkarta (NKTX)
TipRanks · 1d ago
12 Health Care Stocks Moving In Thursday's Intraday Session
Benzinga · 5d ago
Why Is Autoimmune Disease Focused Nkarta Stock Trading Higher On Thursday?
Benzinga · 5d ago
Analysts Offer Insights on Healthcare Companies: Allurion Technologies (ALUR), Perspective Therapeutics (CATX) and Nkarta (NKTX)
TipRanks · 5d ago
More
About NKTX
More
Nkarta, Inc. is a clinical-stage biopharmaceutical company advancing the development of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies for the treatment of patients with autoimmune diseases or hematologic malignancies. It is developing NKX019, a chimeric antigen receptor-natural killer (CAR NK) product candidate targeting the CD19 antigen and NKX101, a CAR NK product candidate targeting cells that display NKG2D ligands. Both product candidates enable an on-demand, off-the-shelf approach involving scaled manufacturing to broaden patient access. Its NKX019 autoimmune program is based on the potential to eliminate the pathologic B cells that produce autoantibodies. Its NKX019 oncology program is based on the potential to treat a variety of B-cell malignancies by targeting the CD19 antigen that is reliably expressed on these types of cancerous cells. Its NKX101 program is designed to enhance the power of innate NK cell biology to detect and kill cancerous cells.
Recently
Symbol
Price
%Change

Webull offers Nkarta Inc stock information, including NASDAQ: NKTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NKTX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading NKTX stock methods without spending real money on the virtual paper trading platform.